NCT05317416 2026-04-16
MagnetisMM-7
Pfizer
Phase 3 Active not recruiting
Clinical Trials
143 trialsNCT06152575 2026-04-16
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Pfizer
Phase 3 Recruiting
NCT05623020 2026-04-15
MagnetisMM-6
Pfizer
Phase 3 Recruiting
NCT06615479 2026-04-14
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Recruiting
NCT03901963 2026-04-13
AURIGA
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04181827 2026-04-13
CARTITUDE-4
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT04923893 2026-04-13
CARTITUDE-5
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05083169 2026-04-13
MajesTEC-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05438043 2026-04-13
A Study of Daratumumab
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT05455320 2026-04-13
MonumenTAL-3
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05552222 2026-04-13
MajesTEC-7
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT05572515 2026-04-13
MajesTEC-9
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT07258511 2026-04-13
TRIlogy-4
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT07518186 2026-04-13
TRIlogy-5
Janssen Research & Development, LLC
Phase 3 Not yet recruiting
NCT03652064 2026-04-08
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT06980480 2026-04-06
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Takeda
Phase 3 Recruiting
NCT04975997 2026-04-03
EXCALIBER-RRMM
Celgene
Phase 3 Active not recruiting
NCT05552976 2026-04-01
SUCCESSOR-2
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT04162210 2026-03-31
DREAMM-3
GlaxoSmithKline
Phase 3 Active not recruiting
NCT05020236 2026-03-27
MAGNETISMM-5
Pfizer
Phase 3 Recruiting
NCT06413498 2026-03-27
iMMagine-3
Gilead Sciences
Phase 3 Recruiting
NCT07452198 2026-03-25
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT05519085 2026-03-24
SUCCESSOR-1
Celgene
Phase 3 Recruiting
NCT03844048 2026-03-20
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie
Phase 3 Active not recruiting
NCT07393282 2026-03-16
LINKER-SMM2
Regeneron Pharmaceuticals
Phase 3 Not yet recruiting
NCT05827016 2026-03-13
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Bristol-Myers Squibb
Phase 3 Recruiting
NCT06158841 2026-03-13
CERVINO
AbbVie
Phase 3 Recruiting
NCT06208150 2026-03-13
MonumenTAL-6
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT07391657 2026-03-12
DURGA-4
AstraZeneca
Phase 3 Recruiting
NCT05730036 2026-03-06
LINKER-MM3
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT06045806 2026-03-05
KarMMa-9
Celgene
Phase 3 Active not recruiting
NCT07138209 2026-02-27
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT03275285 2026-02-09
IKEMA
Sanofi
Phase 3 Completed
NCT07297329 2026-01-29
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Sinocelltech Ltd.
Phase 3 Recruiting
NCT03246529 2026-01-15
GENESIS
BioLineRx, Ltd.
Phase 3 Active not recruiting
NCT06679101 2026-01-08
DREAMM-10
GlaxoSmithKline
Phase 3 Recruiting
NCT06514508 2025-12-16
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
Guangzhou Gloria Biosciences Co., Ltd.
Phase 3 Recruiting
NCT04270409 2025-12-12
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Sanofi
Phase 3 Active not recruiting
NCT02252172 2025-10-20
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT07181239 2025-09-18
Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients
Keymed Biosciences Co.Ltd
Phase 3 Not yet recruiting
NCT02136134 2025-08-29
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT02195479 2025-08-22
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed
NCT06952478 2025-08-15
A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Celltrion
Phase 3 Recruiting
NCT06464991 2025-07-20
FUMANBA-03
Nanjing IASO Biotechnology Co., Ltd.
Phase 3 Recruiting
NCT06508983 2025-06-27
A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
Hangzhou Sumgen Biotech Co., Ltd.
Phase 3 Recruiting
NCT03539744 2025-06-19
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
AbbVie
Phase 3 Active not recruiting
NCT06956170 2025-06-11
DREAMM 8
GlaxoSmithKline
Phase 3 Active not recruiting
NCT03158688 2025-05-09
CANDOR
Amgen
Phase 3 Completed
NCT06868667 2025-05-09
DREAMM 7
GlaxoSmithKline
Phase 3 Active not recruiting
NCT02076009 2025-05-01
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Janssen Research & Development, LLC
Phase 3 Completed